Publicaciones en colaboración con investigadores/as de Klinikum der Universität München (9)

2024

  1. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  2. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2023

  1. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

2021

  1. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic

    British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96

2020

  1. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    International Journal of Cancer, Vol. 146, Núm. 2, pp. 439-448

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2018

  1. Is there a role for HIPEC in ovarian cancer?

    Archives of Gynecology and Obstetrics

  2. Safety and dose modification for patients receiving niraparib

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792